Codexis Reaffirms 2026 Revenue Guidance and Extends Cash Runway to 2028
Codexis (CDXS) reported third-quarter revenues of $19.3 million, marking its fourth consecutive quarter of meeting revenue targets. During the earnings call, CEO Alison Moore emphasized the company's strategic pivot toward providing advanced enzymatic production systems specifically designed for the manufacturing of oligonucleotide medicines. The company reaffirmed its long-term financial outlook, projecting annual revenue between $72 million and $76 million for 2026. Additionally, management highlighted successful capital management strategies that have extended the company's cash runway through 2028, providing a stable foundation for future operational scaling.
Tickers: $CDXS
Topics: earnings enzymatic production oligonucleotide medicines revenue